Regen BioPharma Inc (RGBP) stock
RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026Market cap $92.33KP/E –Yield –
Regen BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Regen BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$803.86K. For fiscal 2025 it was -$338.54K. The highest annual figure on record is -$200.77K in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$338.54K | – |
| FY2024 | Sep 30, 2024 | -$417.22K | – |
| FY2023 | Sep 30, 2023 | -$686.95K | – |
| FY2022 | Sep 30, 2022 | -$339.61K | – |
| FY2021 | Sep 30, 2021 | -$200.77K | – |
| FY2020 | Sep 30, 2020 | -$209.32K | – |
| FY2019 | Sep 30, 2019 | -$756.79K | – |
| FY2018 | Sep 30, 2018 | -$1.43M | – |
| FY2017 | Sep 30, 2017 | -$2.51M | – |
| FY2016 | Sep 30, 2016 | -$2.96M | – |
| FY2015 | Sep 30, 2015 | -$1.98M | – |
| FY2014 | Sep 30, 2014 | -$706.35K | – |
| FY2013 | Sep 30, 2013 | -$319.84K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $24.53K | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$153.71K | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$551.62K | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$123.06K | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$40.76K | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$113.35K | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$61.38K | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$85.40K | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$107.97K | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$101.07K | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$122.78K | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$59.09K | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$85.16K | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$78.84K | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$463.87K | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$97.78K | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$58.91K | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$76.49K | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$106.42K | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$126.83K | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$42.49K | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$12.97K | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$18.48K | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$18.91K | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$16.34K | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$39.33K | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$134.74K | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$189.44K | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$137.72K | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$230.79K | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$198.83K | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$263.29K | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$125.23K | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$447.67K | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$879.59K | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$780.10K | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$553.05K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$659.16K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$533.58K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$676.85K | – |
See a number that looks wrong?